SAT-178 Effect of Androgen Deprivation Therapy on Asthma Exacerbations

Abstract Disclosure: Y. Nayak: None. E. Deol: None. J. Liebich: None. K. Yu: None. Y. Ayoub: None. M. Amini: None. A. Ghimire: None. S. Portillo-Canales: None. P. Patel: None. G. Kamel: None. S. Dhindsa: None. Background: A gender-related disparity exists in asthma morbidity and mortality. Asthma tends to be more common and severe in women compared to men. Epidemiological studies have suggested that serum testosterone (T) concentrations are inversely related to asthma prevalence as well as exacerbations in men. It is not known if male hypogonadism precipitated by androgen deprivation therapy (ADT) has any effect on asthma exacerbations. Methods: This is a retrospective chart review study conducted in the electronic health records of a tertiary care academic hospital. We included adult men with asthma who had at least one interaction with the health system in the last 7 years and had received ADT for prostate cancer. The primary endpoint of the study was to compare the incidence of asthma exacerbations before and after the use of ADT. Asthma exacerbation was defined as any hospitalization due to asthma or usage of oral prednisone if exacerbation was treated in the outpatient setting. Averages are presented as mean ± SD. Comparisons among groups were made by t-test, ANOVA, or non-parametric tests as appropriate. Results: Data were available on 93 men (mean age 75±8 years, BMI 31±7 kg/m2). 89% were White and 11% were Black. The total duration of follow up was 8.8±5.2 years. Asthma was classified as intermittent, mild, moderate, and severe in 46%, 23%, 31% and 0% of patients respectively. Inhaled steroids were used continuously by 51% of the patients. 6% were current smokers and 48% were former smokers. Emphysema or chronic bronchitis were present in 33% of patients. The mean follow-up before starting ADT was 6.1±5.1 years. Patients took ADT for 3.2±3.0 years. GnRH agonist treatment was used in 45% of the patients, while 55% had received more than one type of ADT. 72% of patients had documentation of undetectable serum testosterone concentrations during ADT. The annualized incidence of asthma exacerbations (number of exacerbations/duration of follow up in years) before ADT and during ADT was similar (0.21±1.3 versus 0.06±0.17 per year respectively, p=0.13). Mean follow up after stopping ADT was 1.9±1.8 years. The rate of asthma exacerbations following ADT (0.08±0.34 per year) was similar to the rate during ADT (p=0.31). 67% of patients did not have any exacerbation during the study period. After restricting the analysis to only those with at least one exacerbation (N=31), the rates of exacerbations were not different before, during and after ADT (0.61±2.1, 0.18±0.27 and 0.24±0.57 respectively, p=0.11). Conclusion: Our study shows that ADT in men with asthma did not result in a reduction in asthma exacerbations. These data are informative since prostate cancer and asthma are commonly encountered comorbidities in the ambulatory setting. Presentation: Saturday, July 12, 2025